GLP-1 medications are available as both weekly injections and daily pills, with the choice depending on individual goals, lifestyle, and insurance coverage. Injectable GLP-1s bypass the gut entirely, delivering the drug straight into the body, which is why they have been so effective and reliable. Oral versions have to survive stomach acid, be absorbed through the gut wall, and reach the bloodstream in sufficient quantity to work.
According to Yale Medicine, injectable GLP-1s have outperformed pills in clinical trials, but the difference is smaller than expected. The oral Wegovy pill produced an average weight loss of 13.6% over 64 weeks, compared to roughly 15% for the injectable version over 71 weeks. Wegovy HD came in higher, at 21% weight loss after 72 weeks. Foundayo came in at about 12% over a similar period. The gap may keep closing as some oral options are getting much closer to injectable levels of weight loss.
Side effects of pills and injections are similar, with gastrointestinal symptoms such as nausea, vomiting and diarrhea being the most common. They tend to be mild to moderate and more common when starting treatment or after a dose increase. Side effects often improve as the body adjusts. The Wegovy pill carries a specific concern: vomiting can prevent oral birth control from being fully absorbed. Foundayo has medication interactions including simvastatin and birth control pills.
Out-of-pocket, pills generally run cheaper than injectables. Both the Wegovy pill and Foundayo start at $149 per month for self-pay patients at the lowest dose, compared to injectables that can exceed $1,300 per month without insurance. Insurance coverage generally follows the drug’s approved use, not its form. The choice between injectable and oral depends on lifestyle, medical history, and individual preferences.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.usatoday.com/story/life/health-wellness/2026/05/06/glp-1-shots-vs-pills/89962015007/